Nature 392 (6679 Suppl
The same comprehensive review also reported gas in 12% of participants in one of the analyzed cohorts, indicating that frequency can vary with study population and dosing, as reported in Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes
Journal of Feline Medicine and Surgery
GLP-1 Drugs Changed Peptide Manufacturing Forever: Here Is What the Industry Is Doing to Keep Up In June 2021, the FDA approved Wegovy, the semaglutide-based obesity treatment from Novo Nordisk, and the global pharmaceutical industry entered a chapter it was entirely unprepared for
While early GLP1 drugs focused primarily on diabetes, newer agents, such as tirzepatidebased therapies, have gained traction in treating obesity, raising efficacy expectations and increasing competitive dynamics
Q: Is it safe to use Saxenda with metformin